Introduction
The pharmaceutical industry is experiencing a profound transformation in how it approaches commercial decision-making and insights delivery with a big wave of technology and AI at the doorstep. Market research leaders are increasingly finding themselves at the forefront of this change, driving new ways to generate and deliver insights.
With global pharmaceutical market revenues reaching $1.65 trillion in 2024, Pharma companies generate unprecedented volumes of primary and secondary data. The core challenge for MR leaders is connecting these scattered insights and interpreting it in ways that are fast, flexible, and tailored to real decisions that brand teams can implement.
Market research teams know the risks of misinterpretation - a poorly contextualized analysis can introduce bias and compromise the accuracy of strategic conclusions. Their craft is to interrogate data responsibly, triangulate rigorously, and guide stakeholders toward clarity. Newer technology has the potential to strengthen this approach by enabling iterative, multi-angle analysis at the pace the business needs.
This is where the emergence of agentic artificial intelligence is coming to the fore - a new paradigm that moves beyond traditional dashboards and reports to deliver intelligent, conversational analytics capabilities. MR teams already know how to ask the right questions - AI simply helps them answer more of them, faster, while ensuring insights are contextual, nuanced, and strategically relevant.
Companies such as CustomerInsights.AI are at the forefront of this transformation with the launch of ciATHENA, an Agentic AI and Conversational platform which includes purpose-built Apps for MR Analytics that put powerful capabilities directly into the hands of market research professionals through simple, natural language interactions.
ciATHENA is powered by life sciences domain-specific intelligent agents that understand quantitative, qualitative and unstructured data sources, transformation logic, business rules, decision-making workflows, analytical models and visualizations - enabling MR teams to ask more questions, test more hypotheses, and extract greater value from every research investment.
The challenge: When traditional market research technology hits its limits
Market Research studies have long been the foundation of pharmaceutical brand strategy, helping brand teams understand prescriber behaviour, message recall, and competitive positioning. MR teams continue to bring rigor and depth; what is needed in a faster more demanding world is an analytics delivery model that matches their expertise with the speed and flexibility the business demands
When considering the broader market research portfolio, the typical large healthcare brand team spends nearly $2.5 million a year on market research studies. This figure includes the significant internal costs associated with data collection, analysis, and strategic interpretation. MR teams deliver rigor, but traditional technology means insights can arrive weeks after the research is fielded. These teams know that getting meaningful insights requires thoughtful triangulation and nuance - yet the pace of manual processes makes even their best analysis feel retrospective rather than proactive.
Brand team stakeholders constantly request new hypotheses to be tested based on changing market conditions. While MR teams thrive in new and challenging insight discoveries - applying their expertise to ensure each cut is interpreted correctly, their real limitation is velocity of analytics technology: too much of their time is consumed in preparing new variables for hypothesis testing, regenerating analysis and slides instead of discovering deeper insights.
MR teams also deeply value the opportunity to integrate primary research with secondary and social signals, but current IT and analytics workflows slows their ability to bring those datasets together into a comprehensive story.
By the time integrated analysis workflows are fully executed, the window to act has closed. This can create significant blind spots in commercial understanding during critical periods such as product launches, competitive entries or market access changes when timely and nuanced insights are essential for confident decision-making.
This is why market research needs to evolve not in what it studies, but in how quickly and iteratively MR teams can deliver those insights at scale.
Enter agentic AI: A new paradigm for MR analytics
Agentic artificial intelligence (AI) gives market research teams new leverage over their craft by amplifying the thoughtful analysis workflow of MR teams. It empowers MR leaders to engage with data more flexibly, generate analysis a few different ways and at the speed required to match their expertise.
Unlike traditional BI dashboards or rigid slide decks, agentic AI systems let users ask complex questions like “What changed in Physician perception post-launch?”, “Which segments are driving usage?”, “How does this compare to our last MR study?” and get answers through a natural language interface.
Agentic systems can generate new analysis on demand, reusing past studies and layering in new signals (e.g., social, secondary, CRM) to get more from your MR data.
Advanced analytics solutions such as CustomerInsights.AI's next generation ciATHENA platform are pioneering this transformation. These systems are built around autonomous agents – specialized AI entities that can perform specific tasks, make decisions and collaborate with other agents to achieve complex objectives. In pharmaceutical market research analytics, these agents are domain-specific (e.g. Oncology vs. Gene Therapy), trained on relevant life sciences MR data and business processes to understand the unique challenges and requirements of market research teams. For MR leaders, this means their skill in analysis, interpretation, and storytelling is magnified with less time spent on operations and more time applying expertise to influence cross-functional strategy.This shift represents more than a user interface improvement; this changes the fundamental contract between MR and the business: instead of various teams developing their own interpretations of the data, stakeholders can get validated insights, while MR teams maintain oversight to ensure accuracy and narrative integrity.
Rather than requiring users to master multiple analytics tools and data sources, agentic AI orchestrates a team of intelligent software agents that each perform a specific function working together:
- Data agents handle ingestion across multiple sources (e.g., survey, secondary, social)
- Transformation agents clean and align data to business rules
- Modeling agents run segmentation, driver analysis, and benchmarking
- Insight agents surface contextual answers based on user queries
This architecture means MR users interact with a single, intuitive interface while benefiting from the coordinated work of multiple AI specialists.
The result is not just speed, its repeatability. For e.g. once an ATU has been fielded and loaded into the system, it becomes a reusable, living asset – wave over wave. MR teams (and their partners in marketing, sales, and med affairs) can ask new questions of old data and test new hypothesis, without the risk of misinterpretations.
Agentic AI systems can also operate proactively or with some supervision by continuously monitoring secondary market signals, identifying emerging trends and alerting MR teams to significant changes as they occur based on various key questions and decisions that brand teams are taking.
This post fielding triangulation shifts the role of market research from rearview mirror to a co-pilot. Secondary data including scientific publications, social discourse, and conference data can be layered on top of ATU baselines to support smarter decision making.
And the impact isn’t theoretical. GlaxoSmithKline’s chief data officer estimates that advanced analytics can drive at least a 10% net improvement across revenue and cost outcomes, provided insights are fast, contextual, and actionable.
Transforming Market Research with conversational intelligence
Agentic AI reimagines how market research teams activate research findings. It doesn’t replace primary research, it transforms what happens after the data is collected: faster insight delivery, modular reuse, and broader internal engagement.
ciATHENA’s next-generation solution enables integration of historic survey data, unstructured reports and secondary data to power a dynamic querying interface where users can explore specific hypothesis and insights up to 10X faster. Teams can ask immediate questions and receive contextualized answers based on the most current available data. If a brand team wants to know, “How did perception shift after our competitor’s label update in Q2?”, the insights are immediately accessible via a natural language query, not a new analysis request.
And when sudden events arise such as black box warnings, competitive relabels, or payer formulary shifts MR teams can supplement ATU baselines with social signals, CRM data, or publication analysis. The AI agents surface the impact, enabling near-term response even when no new survey fieldwork has occurred.
Every stakeholder needs something different from a market research study: Marketing looks for message lift; Sales wants territory splits; Med Affairs tracks scientific differentiation. Agentic AI tailors insights by persona and role reducing back-and-forth and allows MR teams to put relevant answers in the hands of the right teams.
Furthermore, unlike static research methodologies, agentic AI systems continuously learn from user interactions, market feedback and outcome data. The system becomes more accurate and relevant over time, adapting to changing market conditions and evolving business needs without requiring manual reconfiguration.
By transforming static reports into living datasets, agentic AI frees MR professionals from repetitive re-delivery. Instead, they can do what they do best: drive new questions, explore richer hypotheses, and uncover deeper meaning from data.
Implementation and impact: Making the transition
Adopting agentic AI doesn’t replace the rigor of market research, it enhances that and allows MR teams to evolve from delivery into strategy, amplifying the thoughtful analysis they already provide.
Because Agentic AI platforms like ciATHENA integrate into existing research workflows and tools (e.g., Excel, PowerPoint, Tableau, R), deployment can often occur in a matter of a couple of weeks. There’s no need to re-platform your stack or retrain your team
Once set up, the conversational nature of agentic AI systems significantly reduces traditional barriers to analytics adoption. Users require minimal technical training, as the primary requirement is intellectual curiosity and familiarity with natural language interactions. This accessibility enables broader participation in data-driven decision-making across commercial organizations.
With 69% of commercial teams increasing analytics budgets and 76% already investing in insight tools【source: Bain Pharma Commercial Study 2024, organizational readiness is high. The barrier isn’t intent - it’s the usability of existing MR analytics stack. MR professionals are strongly positioned to unlock value from tremendous volumes of Pharma data when supported by agentic AI.
Successful implementations begin with one use case and expand organically. Agentic AI doesn’t replace your MR supplier or invalidate primary data; it wraps around it to drive reuse, triangulation, and speed.
MR teams might begin by piping a completed ATU into the platform - allowing business users to ask questions and explore quickly, while MR oversees the context and ensures interpretations are accurate. This turns one dataset into a living asset, reused multiple times and across functions.
From there, MR teams can layer in secondary sources, qualitative findings, and past reports - enriching the dataset and moving the organization up the analytics maturity curve.
Organizations that implement agentic AI report value across three categories:
- Time savings: MR expertise focused on analysis, not mechanics - less manual tabbing, fewer slide rewrites, faster stakeholder response
- Reuse uplift: MR teams enable each research dataset and report to be queried dozens of times, across roles and geographies, maximizing ROI from every research
- Strategic velocity: Faster MR-driven insights fuel quicker market actions especially when layered with forward-looking signals like formulary coverage, patient sentiment, and prescriber networks
A McKinsey study shows that biopharma companies applying advanced analytics realize EBITDA uplifts of 45-75% largely through faster decision cycles, lower insight delivery cost, and higher commercial coordination.
The democratization of analytics capabilities enables broader participation in data-driven decision-making, building organizational intelligence and analytical sophistication. Unlike traditional analytics approaches that require proportional increases in resources and complexity, agentic AI systems can scale insights and analysis without corresponding increases in operational overhead.
Most importantly, agentic AI lets MR teams say “yes” more often without burning out. When insight requests are answered by systems instead of slides, research scales. The future of insights isn’t just faster it’s efficient.
The future of pharma commercial intelligence
As agentic AI technology matures and adoption accelerates, several key trends will shape the future landscape of pharmaceutical intelligence.
Historically, advanced analytics required specialized technical skills, and keeping most stakeholders at arm’s length from the data. With agentic AI, any authorized user like brand lead, medical director, sales ops can query the system directly (with controlled access to data), with MR oversight ensuring data integrity and narrative control.
The real competitive edge will come from being first to detect and act on change signals whether those signals are shifts in prescriber intent, payer coverage, patient sentiment, or competitor activity. Agentic AI, integrated into the MR stack, ensures those signals are captured, contextualized, and delivered before the decision window closes.
Commercial and medical strategies will adapt in near-real time, using continuously refreshed intelligence. In crowded therapeutic areas, the first team to act on a verified signal will win share and agentic AI will make that agility possible.
As MR Agentic systems accumulate usage history and link more data sources, they will move beyond descriptive reporting to predictive and prescriptive guidance suggesting not just what has happened, but what is likely to happen next and what actions to take.
With over 85% of biopharma executives already investing in AI and digital tools [Deloitte Life Sciences Outlook 2024】, the differentiator will no longer be whether you have the technology but how well your teams use it to drive aligned, confident decisions.
Pharmaceutical companies that embrace this transformation – starting with specific use cases such as Agent assisted MR analytics before expanding to broader commercial intelligence applications – will be better positioned to succeed in an increasingly competitive and dynamic market environment.
The fastest path to value is to start small: pick a recent ATU, load it into solutions like ciATHENA, and let MR teams deliver the next wave of insights interactively alongside the traditional decks. Measure engagement, track usage, and build the case for scaling.
For MR leaders, the question is no longer if agentic AI will transform their discipline — it’s how quickly they will harness it to expand their impact and competitive advantage.
Interested in exploring further? Register for a demo:
https://www.customerinsights.ai/request-demo
To see CustomerInsights.AI's next-generation ATU solutions and agentic AI platform in action, contact [email protected]